ViGenCell Inc.

KOSDAQ:A308080 Stock Report

Market Cap: ₩50.7b

ViGenCell Valuation

Is A308080 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Book vs Peers

  • Price-To-Book vs Industry

  • Price-To-Book vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of A308080 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate A308080's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate A308080's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for A308080?

Key metric: As A308080 barely has revenue we use its Price-To-Book Ratio for relative valuation analysis.

The above table shows the Price to Book ratio for A308080. This is calculated by dividing A308080's market cap by their current book value.
What is A308080's PB Ratio?
PB Ratio0.9x
Book₩61.36b
Market Cap₩50.66b

Price to Book Ratio vs Peers

How does A308080's PB Ratio compare to its peers?

The above table shows the PB ratio for A308080 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PBEstimated GrowthMarket Cap
Peer Average1.3x
A420570 J2KBIO
1.8xn/a₩54.5b
A142760 MOA Life Plus
1.2xn/a₩49.5b
A038070 Seoulin BioscienceLtd
0.7xn/a₩55.2b
A389030 GENINUS
1.6xn/a₩44.2b
A308080 ViGenCell
0.9xn/a₩50.7b

Price-To-Book vs Peers: A308080 is good value based on its Price-To-Book Ratio (0.9x) compared to the peer average (1.3x).

Price to Book Ratio vs Industry

How does A308080's PB Ratio compare vs other companies in the KR Biotechs Industry?

4 CompaniesPrice / BookEstimated GrowthMarket Cap
A377740 BioNote
0.3xn/aUS$344.14m
A950210 Prestige BioPharma
0.4xn/aUS$127.73m
A109960 AP Healthcare
0.3xn/aUS$70.10m
A352770 Clinomics
0.5xn/aUS$15.33m
No more companies available in this PB range
A308080 0.9xIndustry Avg. 2.5xNo. of Companies11PB0246810+
4 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Book vs Industry: A308080 is good value based on its Price-To-Book Ratio (0.9x) compared to the KR Biotechs industry average (2.5x).

Price to Book Ratio vs Fair Ratio

What is A308080's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

A308080 PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio0.9x
Fair PB Ration/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate A308080's Price-To-Book Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

J2KBIO

₩54.5b

A bio venture company, provides active ingredients for cosmetics, functional food, and household products from natural materials and microbial fermentation.

A420570

₩9,830.00

7D

6.0%

1Y

n/a

Hugel

₩3.0t

Develops and manufactures biopharmaceuticals in South Korea and internationally.

A145020

₩268,000.00

7D

-3.4%

1Y

75.9%

Dong-A ST

₩544.1b

Develops, manufactures, and markets pharmaceutical products in South Korea and internationally.

A170900

₩62,300.00

7D

-2.0%

1Y

8.6%